eMedicine Specialties > Pediatrics: General Medicine > Infectious Disease

Cytomegalovirus Infection: Follow-up

Author: Mark R Schleiss, MD, American Legion Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota School of Medicine
Contributor Information and Disclosures

Updated: May 8, 2008

Follow-up

Deterrence/Prevention

  • Ultimately, control of cytomegalovirus (CMV) infection, particularly the devastating sequelae of congenital CID, depends on immunization. The major target population for a CMV vaccine is women of childbearing age. Although immunization is unlikely to prevent all congenital infection, immunization will hopefully have a significant and major impact on the prevalence of CID.
  • A vaccine can also be useful in controlling CMV disease in organ transplant recipients. A live attenuated vaccine, the Towne vaccine, showed promise for prevention of CMV disease in studies involving renal transplant recipients reported in the 1980s. However, the Towne strain of CMV is poorly immunogenic, probably because it has been overly attenuated during the process of tissue culture passage.
  • Newer technologies using recombinant chimeric viruses that represent genetic hybrids between Towne virus and a low-passage clinical isolate, the Toledo strain, are currently under investigation as the next generation of live-virus CMV vaccines.
  • Subunit vaccine approaches are also being explored. These use molecularly cloned eucaryotically expressed forms of the major immunogenic CMV envelope protein, gB, and are being actively investigated in clinical trials.
  • A vectored vaccine approach in a genetically engineered poxvirus vector, canarypox, is also under evaluation. In addition to gB, this approach targets the major CTL target, the UL83 gene product.
  • Until the goal of a CMV vaccine is realized, educating women of childbearing age about the risks of CMV and about how to avoid disease transmission are the only control strategies available.
  • Seronegative women who regularly come in close contact with large numbers of young children, particularly in daycare environments, may be at particularly high risk.
  • Behaviors known to be associated with transmission of infection, particularly kissing and sharing eating utensils, can be avoided, and careful handwashing after diaper changes can be stressed.

Patient Education

  • Increased awareness of the complications of congenital CMV infection is needed. With a greater educational effort, women of childbearing age can be better prepared to anticipate risk factors for CMV transmission during pregnancy.14
  • A national CMV registry provides education and support for families affected by congenital CMV infection. Contact the National Congenital CMV Disease Registry at Feigin Center, Suite 1150, 1102 Bates Street, MC 3-2371, Houston, TX, 77030-2399, (832) 824-4387, or visit the Web site at http://www.bcm.tmc.edu/pedi/infect/cmv/.
  • Better education of the risks of CMV infection for young women is a must. The CDC is also an excellent educational resource. 
  • Other foundations provide education and resources for parents interested in learning more about congenital CMV, including the CMV Foundation.

Miscellaneous

Medicolegal Pitfalls

  • Neonatal infections
    • Undertaking a complete evaluation for treatable entities in the evaluation of the newborn with stigmata suggestive of congenital infection is important. Thorough serologic evaluation for congenital HIV infection, syphilis, HSV infection, LCMV infection, toxoplasmosis, and congenital CMV infection is warranted in any infant with features of TORCH illness (eg, small for gestational age [SGA], microcephaly, unusual exanthemata, organomegaly, thrombocytopenia).
    • The potential for development of sensorineural hearing loss or developmental disability is particularly important. Failure to identify infants who may benefit from early intervention programs or hearing aids could delay institution of useful interventions. If antiviral therapy (ganciclovir) for the neonate proves to be effective for prevention of hearing loss in infants with congenital infection, an indication for treatment of such infants could be forthcoming.
  • Adult infections
    • Relatively few pitfalls tend to be considered in adults with CMV infection because such illnesses virtually are always asymptomatic. However, a woman who is CMV seronegative and works in a health care or daycare environment presents a special problem. If such women are contemplating pregnancy, questions often arise about risks in the workplace and the responsibility of employers. Such decisions should be made on an institution-by-institution basis.
    • Women who work in daycare centers have never been shown to be at a higher risk for acquisition of CMV infection than woman in the general population. Programs that attempt to identify patients with active CMV excretion in order to label such babies with precautions, such as "no pregnant caregiver," are not warranted.
    • In every patient-care encounter, consider the possibility of transmission of CMV or other pathogens if universal blood and body fluids precautions are ignored.
    • Simply following appropriate precautions is sufficient to protect caregivers. As a matter of policy, no work restrictions are recommended by most experts irrespective of pregnancy status.

Special Concerns

  • Acquisition of primary CMV infection during pregnancy is a major concern. Women at high risk include those with extensive daycare contact, particularly individuals who work in large daycare facilities in which repeated exposures are common.15  
  • The added risk, if any, for nurses, physicians, or other health care providers is unclear because studies do not uniformly suggest an increased rate of acquisition of primary infection compared with that reported in the general population.
 


More on Cytomegalovirus Infection

Overview: Cytomegalovirus Infection
Differential Diagnoses & Workup: Cytomegalovirus Infection
Treatment & Medication: Cytomegalovirus Infection
Follow-up: Cytomegalovirus Infection
Multimedia: Cytomegalovirus Infection
References
[ CLOSE WINDOW ]

References

  1. Goodpasture EQ, Talbot FB. Concerning the nature of "protozoan-like" cells in certain lesions of infancy. Am J Dis Child. 1921;21:415.

  2. Weller TH, Hanshaw JB. Virological and clinical observation of cytomegalic inclusion disease. N Engl J Med. 1962;266:1233.

  3. Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J Med. Jul 22 1971;285(4):203-14. [Medline].

  4. Schleiss MR, McVoy MA. Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy. Expert Rev Anti Infect Ther. 2004;2 (3):389-403. [Medline].

  5. Kimberlin DW, Lin CY, Sanchez PJ. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003;143(1):16-25. [Medline].

  6. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis. Sep-Oct 1990;12 Suppl 7:S701-10. [Medline].

  7. Dworsky M, Yow M, Stagno S, et al. Cytomegalovirus infection of breast milk and transmission in infancy. Pediatrics. Sep 1983;72(3):295-9. [Medline].

  8. Fowler KB, Pass RF. Risk factors for congenital cytomegalovirus infection in the offspring of young women: exposure to young children and recent onset of sexual activity. Pediatrics. 2006;118:e286-92. [Medline].

  9. Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 7:71. [Medline].

  10. Fowler KB, Dahle AJ, Boppana SB, Pass RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?. J Pediatr. Jul 1999;135(1):60-4. [Medline].

  11. Barton LL, Mets MB. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. Clin Infect Dis. Aug 1 2001;33(3):370-4. [Medline].

  12. Gleaves CA, Smith TF, Shuster EA, Pearson GR. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol. Feb 1985;21(2):217-21. [Medline].

  13. Demmler GJ, Buffone GJ, Schimbor CM, May RA. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis. Dec 1988;158(6):1177-84. [Medline].

  14. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. May 3 2001;344(18):1366-71. [Medline].

  15. Adler SP. Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med. Nov 9 1989;321(19):1290-6. [Medline].

  16. Chou SW. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med. May 29 1986;314(22):1418-23. [Medline].

  17. Demmler GJ. Congenital cytomegalovirus infection and disease. Adv Pediatr Infect Dis. 1996;11:135-62. [Medline].

  18. Demmler GJ. Congenital cytomegalovirus infection treatment. Pediatr Infect Dis J. Nov 2003;22(11):1005-6. [Medline].

  19. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. Jun 14 2002;51(RR-8):1-52. [Medline]. [Full Text].

  20. Kovacs A, Schluchter M, Easley K, et al. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med. Jul 8 1999;341(2):77-84. [Medline].

  21. Plotkin SA. Vaccination against cytomegalovirus, the changeling demon. Pediatr Infect Dis J. Apr 1999;18(4):313-25; quiz 326. [Medline].

  22. Schleiss M, Stanberry L. Herpesvirus infections of the neonatal CNS: Similarities and differences between HSV and CMV. Herpes. 1997;4:74.

  23. Schleiss, MR. Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection. J. Pediatr. 151:564-70. [Medline].

  24. Stagno S, Pass RF, Dworsky ME, et al. Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection. N Engl J Med. Apr 22 1982;306(16):945-9. [Medline].

  25. Tabata T, McDonagh S, Kawakatsu H, Pereira L. Cytotrophoblasts infected with a pathogenic human cytomegalovirus strain dysregulate cell-matrix and cell-cell adhesion molecules: a quantitative analysis. Placenta. 2007;28:527-37. [Medline].

  26. Yow MD. Congenital cytomegalovirus disease: a NOW problem. J Infect Dis. Feb 1989;159(2):163-7. [Medline].

  27. Zhang C, Buchanan H, Andrews W, Evans A, Pass RF. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. J Clin Virol. Mar 2006;35(3):338-42. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

cytomegalovirus, CMV, CMV disease, human CMV, HCMV, cytomegalic inclusion disease, CID, cytomegalovirus disease, inclusion body disease, salivary gland virus, herpes, herpesvirus, human herpesvirus 5, HHV-5, Betaherpesvirinae, human immunodeficiency virus, HIV, mental retardation, cytomegalia, human herpesvirus, herpes simplex virus, hepatitis, toxoplasmosis, rubella, TORCH infection, congenital cytomegalovirus infection, congenital CMV infection
 
intrauterine growth retardation, hepatosplenomegaly, thrombocytopenia, blueberry muffin baby, microcephaly, ventriculomegaly, cerebral atrophy, chorioretinitis, sensorineural hearing loss, intracerebral calcifications, lymphadenopathy, pneumonitis, CMV mononucleosis, Epstein-Barr virus, EBV, pharyngitis, retinitis, esophagitis, gastritis, gastroenteritis, pyloric obstruction, pancreatitis, colitis, cholecystitis,  highly active antiretroviral therapy, HAART, Menetrier disease, atherosclerosis, immunosenescence

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Mark R Schleiss, MD, American Legion Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota School of Medicine
Mark R Schleiss, MD is a member of the following medical societies: American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Medical Editor

David Jaimovich, MD, Chief Medical Officer, Joint Commission International and Joint Commission Resources
David Jaimovich, MD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Leslie L Barton, MD, Professor, Program Director, Department of Pediatrics, University of Arizona School of Medicine
Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

CME Editor

Robert W Tolan Jr, MD, Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility
Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Consulting; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching; sanofi pasteur Grant/research funds Unrestricted research grant; sanofi pasteur  Consulting; sanofi pasteur Honoraria Speaking and teaching; Tap Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine
Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association
Disclosure: None None None

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.